Literature DB >> 30279882

Transcatheter aortic valve implantation in a patient with severe aortic valve stenosis, colon cancer, and obstructive ileus: A case report.

Tetsu Tanaka1, Kazuyuki Yahagi1, Taishi Okuno1, Yu Horiuchi1, Takayoshi Kusuhara2, Motoi Yokozuka3, Sumio Miura2, Kengo Tanabe1.   

Abstract

An 82-year-old woman with symptomatic severe aortic stenosis (AS) developed an obstructive ileus caused by colon cancer. Colectomy was considered a high-risk surgery due to both the severe AS and obstructive ileus. Therefore, we planned placement of a colonic stent for the obstructive ileus. After stenting, we performed transcatheter aortic valve implantation (TAVI) instead of surgical aortic valve replacement (SAVR), because of the risk of bleeding during extracorporeal circulation and the perioperative risk of AVR (Society of Thoracic Surgery predicted risk of mortality: 7.4%). Successful colonic stenting and TAVI allowed a safer colectomy. The period from TAVI to colectomy was 12 days. TAVI could be useful for symptomatic severe AS in high-risk patients prior to non-cardiac surgery, especially for malignant tumors. <Learning objective: In patients with symptomatic severe aortic stenosis, aortic valve replacement is recommended prior to non-cardiac surgery. However, in patients with a malignancy, the complications due to the tumor and the risk of extracorporeal circulation remain a challenge in surgical aortic valve replacement. In such cases, transcatheter aortic valve implantation may be a useful option to reduce the incidence of complications and the time to surgery for the malignancy.>.

Entities:  

Keywords:  Aortic stenosis; Colon cancer; Non-cardiac surgery; Obstructive ileus; Transcatheter aortic valve implantation

Year:  2018        PMID: 30279882      PMCID: PMC6149519          DOI: 10.1016/j.jccase.2018.01.002

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  10 in total

1.  Reduced postoperative blood loss and transfusion requirement after beating-heart coronary operations: a prospective randomized study.

Authors:  R Ascione; S Williams; C T Lloyd; T Sundaramoorthi; A A Pitsis; G D Angelini
Journal:  J Thorac Cardiovasc Surg       Date:  2001-04       Impact factor: 5.209

2.  SURGICAL RISK IN THE CARDIAC PATIENT.

Authors:  J F SKINNER; M L PEARCE
Journal:  J Chronic Dis       Date:  1964-01

3.  2014 ESC/ESA Guidelines on non-cardiac surgery: cardiovascular assessment and management: The Joint Task Force on non-cardiac surgery: cardiovascular assessment and management of the European Society of Cardiology (ESC) and the European Society of Anaesthesiology (ESA).

Authors:  Steen Dalby Kristensen; Juhani Knuuti; Antti Saraste; Stefan Anker; Hans Erik Bøtker; Stefan De Hert; Ian Ford; Jose Ramón Gonzalez-Juanatey; Bulent Gorenek; Guy Robert Heyndrickx; Andreas Hoeft; Kurt Huber; Bernard Iung; Keld Per Kjeldsen; Dan Longrois; Thomas F Lüscher; Luc Pierard; Stuart Pocock; Susanna Price; Marco Roffi; Per Anton Sirnes; Miguel Sousa-Uva; Vasilis Voudris; Christian Funck-Brentano
Journal:  Eur Heart J       Date:  2014-08-01       Impact factor: 29.983

4.  Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial.

Authors:  Josep Rodés-Cabau; Jean-Bernard Masson; Robert C Welsh; Bruno Garcia Del Blanco; Marc Pelletier; John G Webb; Faisal Al-Qoofi; Philippe Généreux; Gabriel Maluenda; Martin Thoenes; Jean-Michel Paradis; Chekrallah Chamandi; Vicenç Serra; Eric Dumont; Mélanie Côté
Journal:  JACC Cardiovasc Interv       Date:  2017-05-17       Impact factor: 11.195

5.  In vitro evaluation of the effect of cardiac surgery on cancer cell proliferation.

Authors:  Shuji Yamamoto; Tatsuya Yoshimasu; Yoshiharu Nishimura; Shunji Uchita; Koji Toguchi; Kentaro Honda; Yoshitaka Okamura
Journal:  Ann Thorac Cardiovasc Surg       Date:  2011       Impact factor: 1.520

Review 6.  Evaluation and management of intestinal obstruction.

Authors:  Patrick G Jackson; Manish T Raiji
Journal:  Am Fam Physician       Date:  2011-01-15       Impact factor: 3.292

7.  Percutaneous balloon aortic valvuloplasty. Acute and 30-day follow-up results in 674 patients from the NHLBI Balloon Valvuloplasty Registry.

Authors: 
Journal:  Circulation       Date:  1991-12       Impact factor: 29.690

8.  Colonic endolumenal stenting devices and elective surgery versus emergency subtotal/total colectomy in the management of malignant obstructed left colon carcinoma.

Authors:  Abdel-Hamid A Ghazal; Walid G El-Shazly; Samer S Bessa; Mohamed T El-Riwini; Ahmed M Hussein
Journal:  J Gastrointest Surg       Date:  2013-01-29       Impact factor: 3.452

9.  Percutaneous aortic balloon valvuloplasty: its role in the management of patients with aortic stenosis requiring major noncardiac surgery.

Authors:  R B Roth; I F Palacios; P C Block
Journal:  J Am Coll Cardiol       Date:  1989-04       Impact factor: 24.094

10.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

Authors:  Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

  10 in total
  1 in total

1.  Transcatheter aortic valve implantation under lower activated clotting time in a patient with hemorrhagic gastric cancer: a case report.

Authors:  Yuki Mitsuta; Takafumi Oyoshi; Takahiro Nonaka; Naoyuki Hirata
Journal:  JA Clin Rep       Date:  2022-10-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.